Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03499379 · ClinicalTrials.gov registry record
Stress Hormones and IUDs
A clinical trial, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- 39
- Enrollment target
NCT03499379: Completed study, sponsored by Oregon Health and Science University.
NCT03499379 is a clinical trial that has completed, run by Oregon Health and Science University. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03499379 has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- 39 participants
- Enrollment target
Study Summary
Determine what kind of side effects women experience in the first year after they start using an intrauterine device.
Primary Outcome
A hair sample of approximately 10 (up to 20) hairs cut close to the scalp 6 months after start of study participation (baseline - IUD insertion) to assess change from baseline to 6 months.
Interventions
- DEVICE Mirena
- DEVICE Paraguard
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2018-04-16 |
| Est. Completion | 2019-12-31 |
What the finished NCT03499379 record still lists
NCT03499379 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 39 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Mirena is the first listed.
NCT03499379 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03499379 about?
NCT03499379 is a clinical study titled "Stress Hormones and IUDs". Determine what kind of side effects women experience in the first year after they start using an intrauterine device.
What is the current status of trial NCT03499379?
This trial is currently completed. The enrollment target is 39 participants. The study started on 2018-04-16. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT03499379?
The interventions under investigation include: Mirena (DEVICE), Paraguard (DEVICE).
Who is sponsoring clinical trial NCT03499379?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI